Oppenheimer analyst Hartaj Singh maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report) today. The company’s shares closed yesterday at $127.90.
Singh covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Regeneron, and Gilead Sciences. According to TipRanks, Singh has an average return of 14.5% and a 47.02% success rate on recommended stocks.
Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $170.20.
See the top stocks recommended by analysts >>
SRPT market cap is currently $12.86B and has a P/E ratio of -20.77.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sarepta Therapeutics (SRPT) Company Description:
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
Read More on SRPT:
